Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Licenses Gencarta to Weizmann Institute and Albert Einstein College of Medicine

NEW YORK, July 23 - Compugen licensed its Gencarta database of annotated genomic, transcription, and proteomic data to the Albert Einstein College of Medicine of Yeshiva University and the Weizmann Institute of Science, the company announced Monday. 

Financial details of the agreements were not disclosed.

"Gencarta complements our established functional genomics program and will greatly accelerate disease-oriented gene discovery by investigators at our institution," Erwin Bottinger, director of the Albert Einstein Biotechnology Center at the Albert Einstein College of Medicine of Yeshiva University, said in a statement.

Compugen, headquartered in Tel Aviv, Israel, released Gencarta in March. The database uses Compugen's Leads algorithm to provide annotation of the transcription factors that bridge genes and proteins. Leads takes into account alternative splicing, in which exons, or coding regions, on one gene can combine in different ways to form different proteins. 

The agreements with Albert Einstein College of Medicine and the Weizmann Institute of Science brings Compugen's Gencarta customers to four. The other licensees are the Japanese pharmaceutical company Kyowa-Hakko Kogyo and Avalon Pharmaceuticals of Gaithersburg, Md.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.